This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Checking in with a prescriber of Novartis' Pluvicto for the treatment of metastatic castration-resistant prostate cancer.

Ticker(s): NVS

Who's the expert?

Institution: Arizona Center for Cancer Care

- Currently manages ~100 prostate cancer pts/yr

- Familiar with PNT2002 and its Phase 3 study data

- A board-certified radiation oncologist and has expertise in the management of breast, prostate and gastrointestinal cancers.

- A member of the American Society for Therapeutic Radiology and Oncology, American Brachytherapy Society, American College of Radiology and the Arizona Radiological Society.

Interview Goal
To better understand the use of Pluvicto as a treatment for MCRPC and see how it compares alongside other treatments in the field.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.